⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTOR News
Citius Oncology, Inc. Common Stock
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
prnewswire.com
CTOR
CTXR
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
prnewswire.com
CTOR
CTXR
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
globenewswire.com
SNGX
AMGN
FOLD
CTOR
TNXP
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
prnewswire.com
CTOR
CTXR
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
prnewswire.com
CTOR
CTXR
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
prnewswire.com
CTOR
CTXR
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
prnewswire.com
CTXR
CTOR
CTXR
CTOR
CTXR
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
prnewswire.com
CTOR
CTXR
CTOR
CTXR
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
prnewswire.com
GTBP
LXEO
ANIX
TEM
CTOR
GTBP
LXEO
ANIX
TEM
CTOR
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe
prnewswire.com
CTOR